NDAOPHTHALMICSOLUTION/DROPS1 Generic Approved
Approved
Apr 1998
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
13
Data completeness
4/8 — Partial
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COSOPT is a fixed-dose combination ophthalmic solution containing dorzolamide (carbonic anhydrase inhibitor) and timolol (beta-blocker) approved in 1998 for glaucoma and ocular hypertension. It reduces intraocular pressure through dual mechanisms: dorzolamide decreases aqueous humor production via enzyme inhibition, while timolol provides additional IOP reduction via beta-blockade. This combination allows twice-daily dosing with enhanced efficacy compared to monotherapy.
$0.135MPart D
LOE ApproachingDeclining
LOE-approaching product with modest Part D penetration signals a mature brand in managed decline, requiring lifecycle-extension or transition strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (13)
Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution
Started Dec 2014
218 enrolled
Open-Angle GlaucomaOcular Hypertension
Patient Preference Comparison of AZARGA Versus COSOPT
Started Sep 2011
112 enrolled
Open-Angle GlaucomaOcular Hypertension
Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Glaucoma
Started Sep 2010
120 enrolled
Glaucoma
Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular Hypertension
Started Apr 2010
70 enrolled
GlaucomaOcular Hypertension
The DIOXXACT Trial(Diurnal IOP and OBF Xalatan vs Xalatan And Cosopt Trial)
Started May 2009
25 enrolled
Eye Disease
Worked on COSOPT at Thea Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.